Founded in 2003, the main business of Lanzhou Kaibo Pharmaceutical Co Ltd (hereinafter referred to as Kaibo Pharma) is peptide drugs and medical bio-materials.
After years of unremitting innovation-driven development, it has developed into a high-tech corporate enterprise integrating R&D, production and sales.
The company has a GMP production plant for peptide drugs, a fine chemical plant, a pharmaceutical and medical materials research institute and a marketing operation center in Shenzhen, as well as two medical bio-material workshops and two injection workshops constructed in the western medical valley in Lanzhou New District in 2016.
Its leading product, thymopentin (an active pharmaceutical ingredient), takes the lead in China's market with a market share of more than 50 percent due to its good quality and low cost.
The company is the only private bio-pharmaceutical and medical bio-materials manufacturer with independent research and development capabilities in Gansu.
It has been identified as a "scientific enterprise with 'explosive growth' potential" by Lanzhou New District and has become a pilot enterprise for the industrialization of high-tech products supported by Lanzhou New District.
The "bio-pharmaceutical and medical bio-materials project" is a key project of Lanzhou New District. The new industrialization base of the project is located in the western medical valley of Lanzhou New District with a total investment of 1.3 billion yuan ($185.4 million). The project construction will be carried out in three phases. It is expected that the annual output value will be 6.8 billion yuan after the project is completed and put into production.
Copyright©2021 China Daily. All rights reserved.